China Resources Jiangzhong Pharmaceutical Co.,Ltd Stocks

China Resources Jiangzhong Pharmaceutical Co.,Ltd functions as a prominent Chinese manufacturer of a wide array of pharmaceutical products for the domestic market. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, such as tablets designed for stomach-strengthening and digestion promotion, lactobacillus tablets, and triple live bifidobacterium enteric-coated capsules. Other significant OTC offerings feature compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, Fritillaria and loquat capsules, bezoar and snake gallbladder Fritillaria liquid, and compound gold melon seed. Beyond pharmaceutical drugs, the company also provides health consumer goods. These range from general nourishing products and rehabilitation nutrition items to specialized solutions for gastrointestinal and liver health. Furthermore, China Resources Jiangzhong Pharmaceutical manufactures prescription drugs. This segment encompasses a broad selection of Traditional Chinese Medicine (TCM) products, including Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules, Zhenju Jiangya tablets, Shuangju granules, Zhikang tablets, and Shuxiong granules. It also produces chemical medications such as lumbrokinase enteric-coated capsules, Rabelagat sodium enteric-coated tablets, and chloroprocaine hydrochloride. Additionally, the company processes and supplies essential medicinal raw materials, including stir-fried Chinese jujube seeds, French pinellia, and vinegar-soaked northern bupleurum. The company, headquartered in Nanchang, China, was established in 1996. It was formerly identified as Jiang Zhong Pharmaceutical Co.,Ltd before officially adopting its current name, China Resources Jiangzhong Pharmaceutical Co.,Ltd, in January 2025.